Global lipoprotein (a) testing trends from 2015 to 2023

• Published in: The American heart journal Vol. 289; pp. 171 - 179
• Main Authors: Hanif, Muhammad, Khan, Laibah Arshad, Kulkarni, Anandita, Bhatia, Harpreet S., Wilkinson, Michael J., Rashid, Ahmed Mustafa, Chew, Nicholas W.S., Banerjee, Subhash, Butler, Javed, Shapiro, Michael D., Khan, Muhammad Shahzeb
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2025; Elsevier Limited
• Subjects: Adult; Adults; Age; Aged; Aorta; Aortic stenosis; Aspirin; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - epidemiology; Carotid arteries; Carotid artery; Carotid Stenosis - blood; Carotid Stenosis - epidemiology; Collaboration; Comorbidity; Congestive heart failure; Coronary artery disease; Coronary Artery Disease - blood; Coronary Artery Disease - epidemiology; Diabetes; Electronic health records; Ethnicity; Family medical history; Female; Genetics; Health risks; Heart diseases; Heart Failure - blood; Heart Failure - epidemiology; Humans; Hypertension; Ischemia; Ischemic Stroke - blood; Ischemic Stroke - epidemiology; Kidney diseases; Lipids; Lipoprotein(a) - blood; Lipoproteins; Male; Middle Aged; Patients; Peripheral Arterial Disease - blood; Peripheral Arterial Disease - epidemiology; Population studies; Retrospective Studies; Risk Assessment; Risk factors; Risk groups; Stroke; Subgroups; Trends; Vascular diseases; Vein & artery diseases; Womens health; United States > US

•Lp(a) testing remains low globally despite known ASCVD risk associations.•Testing increased from 0.009% in 2015 to 0.032% in 2023 across 141 million patients.•<1% of high-risk groups (CAD, HF, PAD) underwent Lp(a) testing in 2023.•Testing was highest in those with a family history of CAD (1.29%...